The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ARCHIVE
ARCHIVE
- ActHIB Recalled due to Contamination
March 21, 2011
- Nihon Medi-Physics Provides Radiocesium Decontaminating Agent Free of Charge
March 21, 2011
- Applications Expected for Inactivated Polio Vaccines at End of 2011
March 21, 2011
- Memantine, Galantamine Enter NHI Price List
March 14, 2011
- EC to Maintain Approval of Avastin + Paclitaxel for Metastatic Breast Cancer
March 14, 2011
- New Task Force to Be Created for Reform of Pharmaceutical Regulations
March 14, 2011
- Restriction on Use of Multiple Drugs in the Elderly Needs Careful Review: Dr Adachi
March 14, 2011
- JPMA Introduces GL for Disclosure of Funds Provided to Healthcare Professionals
March 14, 2011
- Terumo to Launch DuraHeart in April
March 14, 2011
- Zyprexa Applied for Depressive Symptoms Associated with Bipolar Disorders
March 14, 2011
- Terumo's Drug-eluting Stent Recommended for Approval
March 14, 2011
- 14-Day Prescription Limit Will Not Apply to Sonias
March 14, 2011
- 4 Deaths Reported Following Simultaneous Vaccination with Prevnar, ActHIB, DPT Vaccine
March 14, 2011
- Banzel Oral Suspension Approved in the US: Eisai
March 14, 2011
- Tumor Lysis Syndrome Added as Serious ADR Associated with Imatinib, Nilotinib
March 14, 2011
- Eisai to Shift Priority to East Asia
March 14, 2011
- Daiichi Sankyo to Acquire Plexxikon
March 14, 2011
- Bayer Aims to Launch Rivaroxaban in 2012 in Japan
March 14, 2011
- Ajinomoto Aims at Pharma Sales of ¥87.4 Bil. in FY2013
March 14, 2011
- Drastic Reform Necessary to Strengthen Japan's Competitiveness: Mr Mitani of Novartis
March 14, 2011
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…